Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Adma Biologics (ADMA) Leases (2016 - 2025)

Adma Biologics' Leases history spans 11 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Leases fell 22.98% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, down 22.98%, while the annual FY2025 figure was $6.6 million, 22.98% down from the prior year.
  • Leases reached $6.6 million in Q4 2025 per ADMA's latest filing, down from $9.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $10.6 million in Q2 2022 to a low of $6.2 million in Q1 2021.
  • Average Leases over 5 years is $8.7 million, with a median of $9.1 million recorded in 2024.
  • Peak YoY movement for Leases: skyrocketed 140.42% in 2021, then decreased 22.98% in 2025.
  • A 5-year view of Leases shows it stood at $7.3 million in 2021, then soared by 44.37% to $10.5 million in 2022, then decreased by 8.11% to $9.6 million in 2023, then fell by 10.39% to $8.6 million in 2024, then fell by 22.98% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Leases are $6.6 million (Q4 2025), $9.3 million (Q3 2025), and $9.0 million (Q2 2025).